Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-26

Clinical Trial Update: Endometrial Receptivity After GnRH Agonist Triggering [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating endometrial receptivity after GnRH agonist triggering has completed. The sponsor is IVI Madrid.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GnRH agonist triggering (GnRH agonist)

Snippet

Sponsor: IVI Madrid | Conditions: Ovarian Hyperstimulation Syndrome | Phase 4 | Status: COMPLETED